{Reference Type}: Case Reports
{Title}: Long-term use of ultra-low-dose mifepristone for uterine leiomyoma control and safety discussion: A case report.
{Author}: Zhou G;Li Q;
{Journal}: Medicine (Baltimore)
{Volume}: 101
{Issue}: 52
{Year}: Dec 2022 30
{Factor}: 1.817
{DOI}: 10.1097/MD.0000000000032413
{Abstract}: <B>BACKGROUND: </B>In recent years, many clinical trials have used low-dose mifepristone to control uterine fibroids, some of which have achieved good results. However, according to the classic concept, long-term use of mifepristone could induce malignant transformation of the endometrium, and the effect of ultra-low-dose of mifepristone on uterine fibroids is still uncertain. Researchers are short on cases of uterine fibroids treated with mifepristone for long periods (more than a year).<BR><B>METHODS: </B>A 47-year-old woman went to the hospital because of anemia.<BR><B>METHODS: </B>The patient was diagnosed with uterine leiomyoma.<BR><B>METHODS: </B>The patient refused the suggestion of surgery, she was continuously treated with an ultra-low-dose (12.5 mg per 5 days) of mifepristone monotherapy for 4 years.<BR><B>RESULTS: </B>The uterine leiomyoma was stable, anemia and other symptoms disappeared, and the menstrual cycle, liver and kidney function, and tumor markers were normal.<BR><B>CONCLUSIONS: </B>Judging from our case, long-term, ultra-low-dose mifepristone for uterine fibroids treatment was safe and more effective than conventional therapy.